Skip to main content
Close Menu
Logins
Individuals & Patients
Find a Lab View Test Results Pay a Bill Shop for Tests
View Individuals & Patients Page
Providers
Test Menu Provider Login Education & Experts Contact Us
View Providers Page
Health Systems & Organizations Biopharma & Investigators
Nonclinical Research Central Laboratory Services Order a Kit Contact Us
View Biopharma Section

Managing Your Health

Diseases & Therapeutic Areas

  • Cancer & Oncology
  • Neurology
  • Rheumatology
  • More

Treatment Modalities & Methods

Scientific Lab Disciplines

Labs

  • Diagnostic Reference & Specialty Labs
  • Nonclinical Labs
  • Central Labs

News

Careers

Help

Open Menu
Accessibility
Labcorp
Labcorp

Search Submit

Toggle Search
  • Help
Login Help
Animation
On Off
Accessibility
back to Main Menu
Close Menu
Labs & Appointments toggle

Find Locations

For hours, walk-ins and appointments.
Find a lab Modify Appointment Cancel Appointment
Locate Me
Reason for your visit
- Select Service - Routine Labwork Pediatric Collection Employment Wellness with Body Measurement H Pylori Test Employment Drug Testing - Urine Employment Drug Testing - Oral Fluid Rapid Drug Test - Urine Rapid Drug Test - Oral Fluid Saliva Alcohol Screen Hair Collection COVID-19 Unexposed/Symptom Free
Login toggle
  • Patient
  • Provider
Animation
On Off

Search Submit

  • About
  • News
  • Careers
  • Investors
  1. / Home
  2. / Providers
  3. / Rheumatology
  4. / Antinuclear antibody (ANA) testing opitons
Doctor talking on mobile phone while using desktop computer in hospital
mask

Autoimmune Testing

Antinuclear antibody (ANA) testing options

ANA testing can help in the differential diagnosis of many autoimmune disease states, including systemic lupus erythematosus (SLE), drug-induced SLE, mixed connective tissue disease (MCTD), Sjögren syndrome, limited scleroderma (CREST), diffuse scleroderma, rheumatoid arthritis (RA) and autoimmune thyroid disease.1,2

At Labcorp, our ANA tests are performed by immunofluorescence assay (IFA)

Gold standard

The American College of Rheumatology (ACR), ANA task force and the International Consensus on ANA Patterns (ICAP) recommend the IFA as the gold standard for ANA testing3,4

Consistency

Seven patterns are identified automatically, including the titer result5

High-quality results

The detailed review process includes technologist confirmation of all results

ANA by IFA Testing

A positive ANA result may occur in healthy individuals (low titer) or may be associated with a variety of diseases.6,7 Labcorp offers both comprehensive diagnostic profiles and monospecific assays for individual autoantibodies to provide diagnostic and potential prognostic utility for several autoimmune diseases.

Learn more about our ANA testing options in rheumatology

 

ANA testing at Labcorp


ANA tests with titer results reported at a 
1:40 dilution

Number Name
520188 ANA Profile 12 (RDL)
520299 ANA 12 Profile, Do All (RDL)
520180 ANA 12 Plus Profile (RDL)
520175 ANA 12 Plus Profile, Do All (RDL)


ANA test options recommended for initial evaluation with titer results reported at a 1:80 dilution

Number Name
164947 ANA by IFA, Reflex to Titer and Pattern
340897 ANA by IFA, Reflex to 9-biomarker profile, dsDNA, RNP, Sm, SS-A, SS-B, Scl-70, Chromatin, Jo-1, Centromere B by Multiplex Immunoassay
382965 ANA by IFA, Reflex to 11-biomarker Profile, dsDNA, RNP, Sm, SS-A, SS-B, Scl-70, Chromatin, Jo-1, Centromere B, Sm/RNP, Ribosomal P by Multiplex Immunoassay

ANA by IFA is only the first step in diagnosis. We also offer these next steps to help you and your patients find the answers you need.

The Anti-Dense Fine Speckled Protein 70 kDa (DFS70) Ab may help identify individuals who do not have an ANA-associated autoimmune rheumatic disease (AARD) especially in the absence of significant clinical findings.8

The Anti-ENA6 Plus DFS70Ab is a unique screening profile with the novel Anti-DFS70 that may help identify SLE, MCTD, Sjögren syndrome, systemic sclerosis, and idiopathic myopathy (IIM), as well as contributes to the inclusion or exclusion of these AARDs.9 Positive Anti-DFS70, especially when positive in isolation, confers a likelihood ratio of 10.9 for the absence of systemic autoimmune rheumatic disease (SARD).9

Number Name
520301 Anti-ENA6 Plus DFS70Ab Profile
520313 Anti-Dense Fine Speckled Protein 70 kDa (DFS70) Ab

Access Our Comprehensive Autoimmune Portfolio

Autoimmune diseases commonly share clinical manifestations, similar subphenotypes and non-specific autoantibodies. Whether you are a rheumatologist or a primary care provider, we strive to help you differentiate between autoimmune states and obtain an accurate diagnosis with our comprehensive suite of autoimmune testing profiles.

References

1. Fenger M, Wiik A, Høier-Madsen M, et al. Detection of antinuclear antibodies by solid-phase immunoassays and immunofluorescence assays. Clin Chem. 2004;50(11):2141-2147.

2. Tebo AE. Recent approaches to optimize laboratory assessment of antinuclear antibodies. Clin Vaccine Immunol. 2017;24(12):e00270-17. https://doi.org/10.1128/CVI.00270-17.

3. Meroni PL and Shur PH. ANA screening: an old test with new re commendations. Ann Rheum Dis. 2010;69:1420-1422.

4. Chan EK, Damoiseaux J, Carballo OG, et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. Front Immunol. 2015;6:412. doi: 10.3389/fimmu.2015.00412. PMID: 26347739; PMCID: PMC4542633.

5. EUROIMMUN Systems for full automation of IIFT. Luebeck, Germany: Euroimmun; January 2018.

6. Mariz HA, Sato EI, Rodrigues SH, et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2010;63(1):191-200.

7. Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73(1):17-23.

8. Conrad K, Röber N, Andrade LEC, Mahler M. The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol. 2017;52(2):202-216. PubMed 27350273.

9. Fitch-Rogalsky C, Steber W, Mahler M, et al. Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One. 2014: 4;9(4):e93812. PubMed 2470582.

10. Mahler M, Parker T, Peebles CL, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 2012;39:2104-2110.

Labcorp

  • Go to the Labcorp Linkedin page
  • Go to the Labcorp Twitter page
  • Go to the Labcorp Facebook page
  • Go to the Labcorp YouTube page
  • Go to the Labcorp Instagram Page
  • Go to the Labcorp Thread Page

FAQs

Resources

Quick Links

Contact Us

Email Preferences

  • Provider
  • Biopharma

Mobile Footer Menu

  • Labcorp
    • About Us
    • Newsroom
    • Careers
    • Investors
  • FAQs
    • Labs
    • Test Results
    • All Patient
    • All Provider
  • Resources
    • Suppliers & Vendors
    • HIPAA Notice of Privacy Practices
    • No Surprises Act
  • Quick Links
  • Contact Us
    • Patient
    • Provider
    • Biopharma
  • Email Preferences
    • Provider
    • Biopharma
  • Labcorp on Linkedin
  • Labcorp on Twitter
  • Labcorp on Facebook
  • Labcorp on YouTube
  • Labcorp on Instagram
  • Go to the Labcorp Thread Page

Legal Menu

  • Privacy Statement
  • Terms and Conditions
  • Notice of Nondiscrimination
  • Combatting Modern Slavery and Human Trafficking Statement

© 2025 Laboratory Corporation of America® Holdings. All Rights Reserved | Do Not Sell/Share My Personal Information

Content parser: contentLocalUrls |
Total Parsers:1
Memory used: 1.15MB of 20MB
Render time: 2.470 sec., Version: 3.5.4